| scholarly article | Q13442814 |
| P2093 | author name string | H Schmitz | |
| B Kluxen | |||
| I Gigli | |||
| J P Zimmer | |||
| J Schmitz | |||
| M Bögel | |||
| S Aries | |||
| P2860 | cites work | Isolation of a T-Lymphotropic Retrovirus from a Patient at Risk for Acquired Immune Deficiency Syndrome (AIDS) | Q22242256 |
| Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system | Q24301007 | ||
| Human immunodeficiency virus type 1 activates the classical pathway of complement by direct C1 binding through specific sites in the transmembrane glycoprotein gp41 | Q24675546 | ||
| Complement activation by recombinant HIV-1 glycoprotein gp120 | Q28237637 | ||
| The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain | Q29618472 | ||
| Decreased binding of HIV-1 and vasoactive intestinal peptide following plasma membrane fluidization of CD4+ cells by phenytoin | Q33507085 | ||
| Heightened complement sensitivity of acquired immunodeficiency syndrome lymphocytes related to diminished expression of decay-accelerating factor | Q33867535 | ||
| Altered erythrocyte C3b receptor expression, immune complexes, and complement activation in homosexual men in varying risk groups for acquired immune deficiency syndrome | Q34542184 | ||
| Isolation and characterization of a membrane protein from normal human erythrocytes that inhibits reactive lysis of the erythrocytes of paroxysmal nocturnal hemoglobinuria | Q34576112 | ||
| Absence of cytotoxic antibody to human immunodeficiency virus-infected cells in humans and its induction in animals after infection or immunization with purified envelope glycoprotein gp120 | Q34628114 | ||
| Human T-cell lymphotropic virus IIIB glycoprotein (gp120) bound to CD4 determinants on normal lymphocytes and expressed by infected cells serves as target for immune attack | Q34636237 | ||
| Lysis of oncornaviruses by human serum. Isolation of the viral complement (C1) receptor and identification as p15E | Q36339984 | ||
| Lysis of RNA tumor viruses by human serum: direct antibody-independent triggering of the classical complement pathway | Q36359927 | ||
| Complement activation by human monoclonal antibodies to human immunodeficiency virus | Q36638803 | ||
| The control of homologous lysis | Q36705635 | ||
| Identification of human neutralization-inducing regions of the human immunodeficiency virus type 1 envelope glycoproteins | Q36781270 | ||
| Neutralization of human immunodeficiency virus type 1 by complement occurs by viral lysis | Q36795915 | ||
| Isolation of a human erythrocyte membrane protein capable of inhibiting expression of homologous complement transmembrane channels | Q37399677 | ||
| Prospect for prevention of human immunodeficiency virus infection: purified 120-kDa envelope glycoprotein induces neutralizing antibody | Q37399845 | ||
| Lysis of pathogenic and nonpathogenic Entamoeba histolytica by human complement: methodological analysis | Q39042997 | ||
| Human serum lyses RNA tumour viruses | Q39953990 | ||
| HIV and human complement: mechanisms of interaction and biological implication. | Q40769600 | ||
| Presence of a dysfunctional form of CD59 on a CD59+ subclone of the U937 cell line. | Q41478718 | ||
| Functional activity of an HIV-1 neutralizing IgG human monoclonal antibody: ADCC and complement-mediated lysis | Q41626651 | ||
| Direct binding of complement component C1q to human immunodeficiency virus (HIV) and human T lymphotrophic virus-I (HTLV-I) coinfected cells | Q41677253 | ||
| Complement-mediated enhancement of HIV-1 infection of the monoblastoid cell line U937. | Q41718934 | ||
| Antibody- and complement-mediated lysis of HIV-infected cells and inhibition of viral replication | Q41739544 | ||
| Activation of complement on the surface of cells infected by human immunodeficiency virus | Q41744013 | ||
| Lysis of measles virus-infected cells by the purified cytolytic alternative complement pathway and antibody | Q41981035 | ||
| Decreased expression of the membrane inhibitor of complement-mediated cytolysis CD59 on T-lymphocytes of HIV-infected patients | Q44207160 | ||
| Endocytosis and shedding of the decay accelerating factor on human polymorphonuclear cells | Q45161545 | ||
| Tumour necrosis factor-alpha increases the sensitivity of human immunodeficiency virus (HIV)-infected monocytic U937 cells to the complement-dependent cytotoxicity of sera from HIV type 1-infected individuals; role of the gp120 protein | Q45776325 | ||
| Antibodies to human immunodeficiency virus in human sera induce cell-mediated lysis of human immunodeficiency virus-infected cells | Q45842647 | ||
| HIV and HIV-infected cells differentially activate the human complement system independent of antibody | Q46910542 | ||
| The AIDS-associated retrovirus is not sensitive to lysis or inactivation by human serum. | Q53851202 | ||
| Structural properties of the glycoplasmanylinositol anchor phospholipid of the complement membrane attack complex inhibitor CD59 | Q54275110 | ||
| Sera from HTLV-III/LAV antibody-positive individuals mediate antibody-dependent cellular cytotoxicity against HTLV-III/LAV-infected T cells. | Q55243137 | ||
| Complement Activation by gp160 Glycoprotein of HIV-1 | Q57723278 | ||
| Killing of human cytomegalovirus-infected fibroblasts by antiviral antibody and complement | Q58382134 | ||
| Membrane attack complex (MAC)-mediated damage to spermatozoa: protection of the cells by the presence on their membranes of MAC inhibitory proteins | Q67896269 | ||
| Differences between the binding sites of the complement regulatory proteins DAF, CR1, and factor H on C3 convertases | Q68955481 | ||
| A novel membrane glycoprotein capable of inhibiting membrane attack by homologous complement | Q69152113 | ||
| Interaction of non-antibody factors with HIV in plasma | Q72100779 | ||
| Membrane cofactor protein (CD46) protects cells predominantly from alternative complement pathway-mediated C3-fragment deposition and cytolysis | Q72842824 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cytotoxicity | Q246181 |
| P304 | page(s) | 1520-1526 | |
| P577 | publication date | 1995-09-01 | |
| P1433 | published in | Journal of Clinical Investigation | Q3186904 |
| P1476 | title | Antibody-dependent complement-mediated cytotoxicity in sera from patients with HIV-1 infection is controlled by CD55 and CD59 | |
| P478 | volume | 96 |
| Q34749137 | A high-affinity inhibitor of human CD59 enhances complement-mediated virolysis of HIV-1: implications for treatment of HIV-1/AIDS |
| Q33997980 | A novel trifunctional IgG-like bispecific antibody to inhibit HIV-1 infection and enhance lysis of HIV by targeting activation of complement |
| Q56517281 | Analysis of complement-mediated lysis of SIV and SIV-infected cells reveals sex differences in vaccine-induced immune responses in Rhesus macaques |
| Q40518684 | Analysis of the interaction between respiratory syncytial virus and lipid-rafts in Hep2 cells during infection. |
| Q41556124 | Association of complement receptor 2 polymorphisms with innate resistance to HIV-1 infection |
| Q35973601 | Blockage of CD59 Function Restores Activities of Neutralizing and Nonneutralizing Antibodies in Triggering Antibody-Dependent Complement-Mediated Lysis of HIV-1 Virions and Provirus-Activated Latently Infected Cells |
| Q36158037 | CD59 incorporation protects hepatitis C virus against complement-mediated destruction. |
| Q34610122 | Complement and HIV-I infection/HIV-associated neurocognitive disorders |
| Q27490236 | Complement and its role in protection and pathogenesis of flavivirus infections |
| Q37055637 | Complement-HIV interactions during all steps of viral pathogenesis. |
| Q38673539 | Comprehensive Cross-Clade Characterization of Antibody-Mediated Recognition, Complement-Mediated Lysis, and Cell-Mediated Cytotoxicity of HIV-1 Envelope-Specific Antibodies toward Eradication of the HIV-1 Reservoir. |
| Q33955105 | Differential activity of candidate microbicides against early steps of HIV-1 infection upon complement virus opsonization |
| Q36090335 | Evasion and interactions of the humoral innate immune response in pathogen invasion, autoimmune disease, and cancer |
| Q41741684 | Functions of Antibodies. |
| Q40657302 | Glycosylphosphatidylinositol Anchor Deficiency Attenuates the Production of Infectious HIV-1 and Renders Virions Sensitive to Complement Attack |
| Q30248405 | HIV-1 and hijacking of the host immune system: the current scenario |
| Q36827324 | Hepatitis C virus suppresses C9 complement synthesis and impairs membrane attack complex function |
| Q33742139 | Human Immunodeficiency Virus Playing Hide-and-Seek: Understanding the TFH Cell Reservoir and Proposing Strategies to Overcome the Follicle Sanctuary |
| Q38139934 | Innate immune evasion strategies by human immunodeficiency virus type 1. |
| Q50116524 | Integrity of Glycosylation Processing of a Glycan-Depleted Trimeric HIV-1 Immunogen Targeting Key B-Cell Lineages |
| Q34039343 | NF-κB and enhancer-binding CREB protein scaffolded by CREB-binding protein (CBP)/p300 proteins regulate CD59 protein expression to protect cells from complement attack |
| Q85097634 | Paroxysmal nocturnal hemoglobinuria clones are not present in HIV positive patients |
| Q34218827 | Provirus activation plus CD59 blockage triggers antibody-dependent complement-mediated lysis of latently HIV-1-infected cells |
| Q41413269 | Role of complement and Fc receptors in the pathogenesis of HIV-1 infection |
| Q35134722 | Role of complement in the control of HIV dynamics and pathogenesis |
| Q35976953 | The Trojan exosome hypothesis |
| Q28275986 | The good and evil of complement activation in HIV-1 infection |
| Q33688595 | Viral complement regulatory proteins |
| Q35122624 | Viral mimicry of the complement system |
Search more.